To include your compound in the COVID-19 Resource Center, submit it here.

Infergen interferon alfacon-1 regulatory update

FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a warning letter to Kadmon's CEO Samuel

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE